Case Study 27.2 — One Mechanism, Two Consequences: The GnRH Flare

Chapter 27 · Peptides in Oncology

Why this case

There is a sentence that appears constantly in peptide marketing: it works with your body's own signaling, so it doesn't have side effects the way drugs do.

This case study is the counterexample that should end that sentence forever. It follows a single principle of physiology — Chapter 3's finding that the hypothalamic-pituitary axis responds to the pattern of hormone release rather than its presence — from a laboratory observation, through a therapy that has treated millions of patients, into a complication that can cost a man the use of his legs, and out again into a second generation of drugs designed specifically to avoid it.

The therapy and the complication are the same mechanism. Not a mechanism and an off-target effect. The same one, observed at different times.

Step 1: The physiology (Chapter 3 §3.5)

GnRH is released from the hypothalamus in pulses, roughly every one to two hours. The pituitary gonadotroph responds to that rhythm. Give it the rhythm and the axis runs. Give it a continuous, unbroken signal and the receptor desensitizes, is internalized and downregulated, and gonadotropin output collapses.

This is genuinely counterintuitive on first meeting. More signal, applied without pause, produces less output. It is one of the most important facts in endocrinology and it is the reason a stimulator can be turned into a suppressor without changing what it does at the receptor at all.

Step 2: The therapy

Prostate cancer, in its hormone-sensitive phase, runs on testosterone. Charles Huggins demonstrated in 1941 that the disease regresses when androgens are withdrawn — work that earned a share of the 1966 Nobel Prize in Physiology or Medicine. Huggins achieved withdrawal surgically or with estrogen. Both worked. Both had obvious drawbacks: one is irreversible, the other has its own toxicity.

The peptide solution came in the 1980s. Take the ten-residue GnRH decapeptide. Substitute a D-amino acid at position 6 so proteases cannot cleave it. Modify the C-terminal end. Formulate the result into a depot that releases steadily over one, three, four, or six months. The pituitary now receives a GnRH signal that never stops.

The axis does what the physiology said it would do. Receptors desensitize, LH falls, the testes stop producing testosterone, and within a few weeks testosterone sits at castrate levels for as long as the drug is given. Androgen deprivation therapy — reversible, titratable, and the backbone of hormone-sensitive prostate cancer treatment for four decades.

Step 3: The complication

Desensitization takes time. Before it happens, an agonist agonizes.

THE FIRST FOUR WEEKS

  week 0 ─────► week 1 ─────► week 2 ─────► week 4
   inject      LH surge      peak T,        castrate
   agonist     T rising      then falling   T reached
                  ▲
                  │
            THE FLARE WINDOW
      the drug is doing exactly what
      an agonist does, on its way to
      doing exactly what it was given for

For most patients this window is clinically uneventful. For a man with extensive metastatic disease — particularly in the spine — it is not. A transient rise in the hormone feeding the tumor can produce a transient increase in tumor activity: worsening bone pain, worsening urinary obstruction, and, in the worst case, spinal cord compression. That is the flare, and it is a documented and anticipated clinical problem rather than a theoretical one.

The workaround is antiandrogen cover. An androgen receptor blocker such as bicalutamide is started shortly before or alongside the agonist and continued through the surge window. Testosterone may rise; it cannot reach the receptor that matters. The antiandrogen is then usually stopped.

It is an elegant fix, and it is worth noticing what kind of fix it is: a second drug, given for a defined window, to manage a predictable consequence of the first drug's mechanism.

Step 4: The second generation

The obvious alternative is to block the receptor rather than exhaust it. An antagonist never stimulates, so there is no surge to cover.

That took longer to build, and the record shows why. A peptide antagonist must bind tightly enough to exclude endogenous GnRH, must not trigger the signaling conformation, and must maintain occupancy continuously, because the moment blockade lapses the axis restarts. Early candidates ran into histamine-release reactions. Abarelix reached US approval in 2003 and was withdrawn from the US market within a couple of years, with systemic allergic reactions among the concerns. Degarelix, a peptide antagonist approved in 2008, achieved castrate testosterone within days and without a surge. Later still came relugolix, an oral option — and a small molecule, not a peptide, which is exactly why it can be swallowed.

And the naming convention Chapter 1 asked you to memorize now does real clinical work:

One letter. Opposite initial effect. For a patient with impending spinal cord compression, that letter identifies which of two otherwise-equivalent drugs is safe to start today.

The lesson to extract

Mechanism does not partition into good effects and bad effects. The same receptor biology that produces the therapy produces the complication, and no amount of naturalness, endogeneity, or physiological plausibility changes that. The flare is not an impurity, not an idiosyncratic reaction, not an off-target action. It is the drug working.

Hold that against the marketing claim this case opened with. A compound that acts on an endocrine axis will produce the physiology of acting on that axis — including the parts nobody wanted. When a seller tells you their peptide "supports" an axis "without the downsides," they are describing a molecule that either does not engage the axis meaningfully or has not been observed carefully enough for anyone to know.

Discussion questions

1. Explain, without using the words agonist or antagonist, why continuous stimulation of the GnRH receptor eventually produces suppression. Then explain why the same fact predicts an initial surge. Aim your explanation at someone with no biology background.

2. Is the flare a side effect? Argue the case both ways. Then decide which classification is more useful for (a) a regulator writing a label, (b) a clinician deciding what to prescribe, and (c) a reader trying to evaluate peptide marketing. Note whether your answer differs across the three.

3. GnRH agonists reached the clinic roughly two decades before workable antagonists. The chapter argues this reflects tractability rather than merit. Discuss what that implies about first-in-class drugs generally, and name one other place in medicine where the first solution to a problem was the one that was easiest rather than the one that was best.

4. Antiandrogen cover is a second drug given to manage the predictable consequence of a first drug's mechanism. Discuss when that pattern is good medicine and when it is a warning sign. What distinguishes the two?

5. Androgen deprivation therapy produces hot flashes, loss of libido and erectile function, fatigue, muscle loss, fat gain, bone density loss, and metabolic changes. The chapter argues that evaluating this toxicity profile without naming the comparator is "a category error." Discuss what the comparator actually is in metastatic hormone-sensitive prostate cancer, and how you would explain that framing to a patient without appearing to dismiss the burden.

6. Relugolix is oral because it is not a peptide. Discuss what this single fact teaches about the limits of peptides as a drug class — and then discuss why the chapter insists on stating it, given that it makes oncology's peptide record look slightly less impressive. What does the willingness to state it tell you about how the rest of the book's claims should be read?